Evidence map›Paper›PMID 25451650›Full record

ArticleGastroenterology2015

Molecular subtyping of colorectal cancer: time to explore both intertumoral and intratumoral heterogeneity to evaluate patient outcome.

Eric R Fearon, John M Carethers

Abstract readEditorialComment
In one paragraph

Article in Gastroenterology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed.

  1. Article
  2. Anthelmintic Drugs as Emerging Immune Modulators in Cancer.International journal of molecular sciences · 2023
    Review
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Review
  9. Article
  10. Article
  11. Review
  12. Article
  13. Article
  14. Segmental distribution of some common molecular markers for colorectal cancer (CRC): influencing factors and potential implications.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2016
    Review
  15. Article
  16. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

2 authors.

Eric R FearonDivision of Molecular Medicine and Genetics, Department of Internal Medicine and Comprehensive Cancer Center, University of Michigan, Ann Arbor, Michigan. Electronic address: fearon@med.umich.edu.
John M CarethersDivision of Gastroenterology, Department of Internal Medicine and Comprehensive Cancer Center, University of Michigan, Ann Arbor, Michigan.

Funding

CDX2 TUMOR SUPPRESSOR PATHWAY DEFECTS IN COLON CANCERR01CA082223 · NCI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI FEARON, ERIC R. · 1999 to 2015
$3.9M
MICROSATELLITE INSTABILITY &DNA MISMATCH REPAIR SYSTEMR01DK067287 · NIDDK · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI CARETHERS, JOHN M · 2005 to 2015
$3.2M
Inflammatory Differentiation of Colorectal Cancer Among African AmericansU01CA162147 · NCI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI CARETHERS, JOHN M · 2012 to 2016
$1.4M
CDX2 Tumor Suppressor Pathway Defects in Colon CancerR56CA082223 · NCI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI FEARON, ERIC R. · 2009 to 2009
$306k
NCI NIH HHS CA082223NCI NIH HHS CA162147NCI NIH HHS R01 CA082223NCI NIH HHS R56 CA082223NCI NIH HHS U01 CA162147NIDDK NIH HHS DK067287NIDDK NIH HHS R01 DK067287
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

CpG IslandsDNA MethylationDNA Mismatch RepairMicrosatellite InstabilityMutationAdenocarcinomaBiomarkers, TumorColonic NeoplasmsColorectal NeoplasmsFemaleHumansMaleProto-Oncogene ProteinsProto-Oncogene Proteins B-rafProto-Oncogene Proteins p21(ras)ras ProteinsBiomarkers, TumorBRAF protein, humanKRAS protein, humanProto-Oncogene ProteinsProto-Oncogene Proteins B-rafProto-Oncogene Proteins p21(ras)ras Proteins

Identifiers

PMID25451650
PMCPMC4471844

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.